Predictors of initiation and completion of Shingrix vaccination in immunocompetent adults newly eligible for vaccination from 2018–2024 Authors: Nina B Masters, Karen Gilbert Farrar, Duy Do, Brianna M G Cartwright Published: 2026 ABSTRACT ABSTRACTThe Shingrix vaccine has been recommended for immunocompetent adults aged ≥50 y since October 2017. It is important to assess recent trends and predictors of Shingrix vaccination among those newly eligible to evaluate acceptability, desirability, and uptake of the vaccine. In this retrospective cohort study, we used electronic health record data with linked medical and pharmacy claims data from Truveta. Immunocompetent adults turning 50 between 2018 and 2024 with at least 1 y of continuous enrollment after their 50th birthday were included. We estimated the cumulative incidence of vaccination by eligibility year and assessed series completion at 6 and 12 m. Multivariable logistic regression identified predictors of initiation and series completion. Among 153,899 adults (57.0% female; 62.2% White), 9.9% received ≥1 Shingrix dose within 1 y of eligibility. One-year uptake increased from 2.6% (2018 cohort) to 14.0% (2024 cohort). Three-year uptake reached 27.5% among those eligible in 2022. Among initiators within the first year of eligibility, 62.6% completed the series within 6 m and 74.5% within 12 m. Influenza vaccination during a person’s 50th y was the strongest non time-based predictor of Shingrix vaccination (odds ratio 1.96, 95% CI 1.88–2.03). Women and Asian adults had higher odds of initiation, whereas Black or African American adults, Medicaid/CHIP enrollees, rural residents, and those with cardiovascular disease had lower odds. Shingrix uptake among newly eligible adults has increased rapidly since 2018. Persistent sociodemographic disparities highlight the need for targeted strategies to improve equitable vaccine uptake.KEYWORDS: Shingrix, shingles, vaccination, herpes zoster, vaccination uptake Background Herpes zoster (HZ), commonly known as shingles, is a reactivation of latent varicella zoster virus (VZV) infection. While primary VZV infection manifests as varicella, or chickenpox, in childhood, HZ occurs later in life and is characterized by a painful, vesicular rash that can lead to long-term complications, including post-herpetic neuralgia. HZ is extremely common – approximately one in three individuals in the United States will develop HZ during their lifetime.1 The first vaccine licensed for prevention of HZ, a live attenuated vaccine (Zoster Vaccine Live; ZVL), was approved in 2006 but achieved relatively modest uptake and demonstrated waning effectiveness over time.2,3 In October 2017, recombinant zoster vaccine (RZV; Shingrix) was approved by the U.S. Food and Drug Administration and subsequently recommended by the Advisory Committee on Immunization Practices (ACIP) for immunocompetent adults aged ≥50 y. RZV was preferentially recommended over ZVL due to substantially higher efficacy.4,5 ACIP further recommended all age-eligible adults receive Shingrix, including those previously vaccinated with ZVL.4 In 2021, ACIP recommended Shingrix for immunocompromised adults aged 19–49 y, expanding the population eligible to receive the vaccine.6 The Shingrix series consists of two 0.5 mL intramuscular doses administered 2–6 months apart.4 Beyond prevention of HZ, emerging evidence suggests that HZ vaccination may confer additional benefits for cognitive health. While the mechanisms are not entirely known, neurotropic herpesviruses are thought to play a role in the development of dementia, and thus preventing reactivation of these viruses may be protective.7 Studies leveraging natural experiments using electronic health record (EHR) data from Wales and Australia found that eligibility to receive ZVL vaccination was associated with a reduced incidence of dementia over subsequent follow-up.8,9 More recently, a real-world evidence study using US claims data reported a 32% reduction in incident dementia among individuals fully vaccinated with Shingrix between 2017 and 2022.10 As new research has emerged highlighting these potential downstream benefits of HZ vaccination, it is critical to understand patterns and predictors of vaccine uptake, especially among those newly eligible for the vaccine. Prior work examining ZVL uptake found vaccination to be more common among individuals with higher socioeconomic status, prior influenza vaccination, and residence in areas with higher local vaccination rates.11 Early evidence suggests that uptake of Shingrix remains suboptimal, with first dose coverage estimated at ~17% in 2021, with pronounced racial and sex-based disparities.12,13 Studies have found high completion of the two-dose series among initiators, ~70% by 6 months and ~80% by 12 months,14 but reactogenicity and access barriers may influence completion patterns. Studies have not explored patterns of uptake and completion among 50-y-olds newly eligible for the vaccine. In this study, we sought to characterize sociodemographic, clinical, and utilization-based predictors of Shingrix vaccination among immunocompetent adults newly eligible for the vaccine, evaluate uptake of one and two doses, and describe temporal trends in vaccination since ACIP recommendation. Materials and methods Data source We conducted a retrospective cohort study using a subset of Truveta Data, a nationwide database of US health systems with over 130 million individuals spanning all 50 states, representing approximately 20,000 clinics and 900 hospitals.15 Truveta Data provide structured demographic variables, encounter details, diagnoses, immunizations, procedures, medication administration and dispensing relevant to this analysis. Data undergo syntactic and semantic normalization and are then deidentified by expert determination under the HIPAA (Health Insurance Portability and Accountability Act) Privacy Rule. This analysis used linked closed medical and pharmacy claims to ensure robust capture of immunizations provided outside a traditional healthcare setting (i.e., in a pharmacy). This study used only de-identified patient records and therefore did not require Institutional Review Board approval. Data were accessed on February 26, 2026. Population and design Individuals were included if they turned 50 y of age (index date) between 2018 and 2024 with at least one outpatient visit in a Truveta constituent health system in their 49th y of life, and a second outpatient visit during their 47–48th y of life. These outpatient visits were required to improve capture of baseline medical history and comorbidities. Individuals who received a shingles vaccine prior to their 50th birthday (with a 30-d grace period) were removed from analysis. Individuals were also required to have at least 1 y of continuous medical and pharmacy enrollment after their 50th birthday, with a maximum gap period of 30 d allowed. The 30-d allowance was included to account for administrative delays in enrollment data while patients maintain continuity of care. We also conducted additional analyses exploring 2- and 3-y of continuous enrollment. Individuals were excluded if they had any evidence of immunosuppressive medication use or immunocompromising conditions in either EHR or claims data prior to their 50th birthday that would alter Shingrix eligibility, including HIV infection, malignancy, inborn error of immunity disorders, or history of organ transplantation. Persons with unknown sex (n = 165) and individuals who received >3 Shingrix vaccines (n = 168) were removed due to potential anomalies with those patient records. Shingrix and flu vaccination Shingrix vaccination was defined by CVX, CPT, RxNorm, and NDC codes to capture administrations in both health care and pharmacy settings [see supplemental Table S1]. Vaccinations were pulled from structured EHR data (including immunization, procedure, charge, and medication administration, and medication dispense records) as well as linked medical and pharmacy claims. Multiple records for the same vaccination given on the same date were deduplicated, and Shingrix doses administered less than the minimum 4 weeks4 apart were removed due to potential administration or recording errors. Flu vaccinations were similarly captured by CVX, CPT, HCPCS, and NDC codes for different formulations used across the study period. Flu vaccinations received in one’s 50th y were included in models as a predictor of Shingrix vaccine receipt, and as such, were censored by the date of Shingrix vaccination – flu vaccines had to be received on the same day or before Shingrix in a patient’s 50th y to be included in the model. Statistical analysis One-, two- and three-year cumulative incidence (calculated as 365, 730, and 1095 d, respectively after a patient’s 50th birthday) of Shingrix immunization were calculated by subsetting the population to those with 1, 2, and 3 y of continuous enrollment to guarantee full follow up. Each population was stratified by year of eligibility. We accounted for an expected data lag in claims due to the adjudication process by administratively truncating eligibility in the final study years by 3 m. Specifically, individuals who turned 50 between January and September 30, 2024, were included for the 2024 eligibility year, with 1-y follow up extending through September 2025. Similarly, individuals included in 2-y and 3-y follow up analyses were required to have turned 50 by September 30th of 2023 and 2022, respectively, allowing follow up through September 2025. Completion of the series at 6 m, 1 y, and 2 y was identified by having a second shingles dose within 180, 365, and 730 d of the first dose. Primary exposures of interest included sociodemographic characteristics (age, sex, race, ethnicity) and clinical comorbidities (type 2 diabetes, cardiovascular disease, and obesity documented in EHR or claims at any time before the patient’s 50th birthday). Type 2 diabetes and cardiovascular disease were determined through SNOMED CT and ICD10 codes, while obesity also leveraged observation data, directly characterizing a patient’s BMI measurements extracted from the EHR. We used an indicator of healthcare utilization, specifically the number of outpatient visits by the patient in the year prior to their 50th birthday. Patients were classified as ‘high utilizers’ if they had six or more outpatient visits during this year, representing the 80th percentile of the variable’s distribution. We also explored whether the patient had evidence of a shingles infection prior to their index date and examined insurance type from claims enrollment: commercial, Medicaid, and other (including individuals with Medicare). To explore predictors of vaccination, we fit a multivariable logistic regression model for receipt of any dose of Shingrix in the first year of eligibility. Because time to vaccination differed substantially by eligibility year, calendar year of eligibility was included as a categorical variable. We also generated unadjusted Kaplan–Meier curves to describe cumulative incidence of shingles vaccination within 2 y of eligibility, stratified by year of eligibility, with administrative censoring for disenrollment. Additionally, a sensitivity analysis was performed using a Cox Proportional Hazards model with baseline hazard stratified by year of eligibility, including administrative censoring at 12 months. All P-values were from 2-sided tests, and results were deemed statistically significant at P < .05. Missing and unknown values of variables were captured in an ‘unknown’ category and included in analyses. Analyses were conducted in R, version 4.4.1 (R Project for Statistical Computing), within a cloud-based notebook environment leveraging Apache Spark, version 3.5 (The Apache Software Foundation). Results Population and Shingrix vaccine uptake The study population included 153,899 adults who became eligible for Shingrix between 2018 and 2024 (Table 1). Across eligibility cohorts, the population was majority female (57.0%) and White (62.2%). Clinical comorbidities became more prevalent across successive eligibility cohorts. Nearly half of the population had cardiovascular disease (50.0%) or obesity (49.8%), with both conditions increasing substantially over time. The prevalence of type 2 diabetes was 17.4%. Overall, 15,223 adults (9.9%) received at least one Shingrix dose within their first year of eligibility. Table 1.Population variables by year of Shingrix eligibility, 2018–2024.CharacteristicOverall2018201920202021202220232024N = 153,899N = 18,903N = 18,675N = 25,842N = 27,274N = 22,634N = 20,776N = 19,795Sex Female87,769 (57.0%)10,893 (57.6%)10,618 (56.9%)14,526 (56.2%)15,561 (57.1%)12,957 (57.2%)11,867 (57.1%)11,347 (57.3%) Male66,130 (43.0%)8,010 (42.4%)8,057 (43.1%)11,316 (43.8%)11,713 (42.9%)9,677 (42.8%)8,909 (42.9%)8,448 (42.7%)Race Asian9,141 (5.9%)1,093 (5.8%)1,025 (5.5%)1,468 (5.7%)1,575 (5.8%)1,408 (6.2%)1,374 (6.6%)1,198 (6.1%) Black or African American20,347 (13.2%)2,244 (11.9%)2,270 (12.2%)3,487 (13.5%)4,021 (14.7%)3,163 (14.0%)2,678 (12.9%)2,484 (12.5%) Other10,876 (7.1%)1,108 (5.9%)1,138 (6.1%)1,639 (6.3%)1,962 (7.2%)1,805 (8.0%)1,594 (7.7%)1,630 (8.2%) White95,752 (62.2%)12,746 (67.4%)12,307 (65.9%)16,416 (63.5%)16,495 (60.5%)13,524 (59.8%)12,477 (60.1%)11,787 (59.5%) Unknown17,783 (11.6%)1,712 (9.1%)1,935 (10.4%)2,832 (11.0%)3,221 (11.8%)2,734 (12.1%)2,653 (12.8%)2,696 (13.6%)Ethnicity Hispanic or Latino18,530 (12.0%)1,786 (9.4%)1,914 (10.2%)2,567 (9.9%)3,122 (11.4%)3,066 (13.5%)2,949 (14.2%)3,126 (15.8%) Not Hispanic or Latino117,065 (76.1%)14,966 (79.2%)14,578 (78.1%)20,041 (77.6%)20,615 (75.6%)16,861 (74.5%)15,454 (74.4%)14,550 (73.5%) Other/Unknown18,304 (11.9%)2,151 (11.4%)2,183 (11.7%)3,234 (12.5%)3,537 (13.0%)2,707 (12.0%)2,373 (11.4%)2,119 (10.7%)N Outpatient Visits Year Before 50th Birthday*4 (6)3 (6)3 (6)3 (6)3 (6)4 (7)4 (6)4 (6)Shingles History3,882 (2.5%)324 (1.7%)353 (1.9%)538 (2.1%)660 (2.4%)623 (2.8%)689 (3.3%)695 (3.5%)Urbanicity Rural12,616 (8.2%)1,671 (8.8%)1,588 (8.5%)2,336 (9.0%)2,355 (8.6%)1,894 (8.4%)1,484 (7.1%)1,288 (6.5%) Urban115,620 (75.1%)14,344 (75.9%)13,967 (74.8%)19,369 (75.0%)20,332 (74.5%)16,921 (74.8%)15,773 (75.9%)14,914 (75.3%) Unknown25,663 (16.7%)2,888 (15.3%)3,120 (16.7%)4,137 (16.0%)4,587 (16.8%)3,819 (16.9%)3,519 (16.9%)3,593 (18.2%)CVD^76,942 (50.0%)6,800 (36.0%)7,943 (42.5%)12,204 (47.2%)13,985 (51.3%)12,369 (54.6%)11,850 (57.0%)11,791 (59.6%)Obesity^76,667 (49.8%)7,693 (40.7%)8,500 (45.5%)12,166 (47.1%)13,686 (50.2%)11,867 (52.4%)11,452 (55.1%)11,303 (57.1%)T2D^^26,784 (17.4%)2,696 (14.3%)3,010 (16.1%)4,226 (16.4%)4,930 (18.1%)4,277 (18.9%)3,941 (19.0%)3,704 (18.7%)Insurance Type Commercial111,364 (72.4%)15,392 (81.4%)13,180 (70.6%)17,520 (67.8%)17,876 (65.5%)15,179 (67.1%)16,170 (77.8%)16,047 (81.1%) Medicaid/CHIP40,213 (26.1%)3,184 (16.8%)5,177 (27.7%)7,871 (30.5%)8,970 (32.9%)7,172 (31.7%)4,314 (20.8%)3,525 (17.8%) Other+2,322 (1.5%)327 (1.7%)318 (1.7%)451 (1.7%)428 (1.6%)283 (1.3%)292 (1.4%)223 (1.1%)*Mean (Standard Deviation).**There was a higher degree of unknown urbanicity due to the utilization of a time-optimized profile in the data, which leveraged quasi-identifiers for calendar time and led to increased suppression of zipcode level data.^Annual prevalence of CVD and obesity both increased substantially over the study period, which could be attributable to a combination of epidemiologic trends and rising rates of CVD and obesity,16 but also potentially increased ascertainment or documentation of these conditions in EHRs.^^Type 2 Diabetes+ Other insurance includes those who are dual eligible, have family care, SNP, or Medicare, which in this population of 50-y-olds likely represents individuals with a qualifying disability. Population variables by year of Shingrix eligibility, 2018–2024. *Mean (Standard Deviation). **There was a higher degree of unknown urbanicity due to the utilization of a time-optimized profile in the data, which leveraged quasi-identifiers for calendar time and led to increased suppression of zipcode level data. ^Annual prevalence of CVD and obesity both increased substantially over the study period, which could be attributable to a combination of epidemiologic trends and rising rates of CVD and obesity,16 but also potentially increased ascertainment or documentation of these conditions in EHRs. ^^Type 2 Diabetes+ Other insurance includes those who are dual eligible, have family care, SNP, or Medicare, which in this population of 50-y-olds likely represents individuals with a qualifying disability. Completion of the Shingrix series ACIP guidelines recommend vaccination series completion within 2–6 m of the first dose. In this study, among those who received Shingrix within their first year of eligibility, 9,531 (62.6%) completed the series within 6 m and 11,340 (74.5%) completed the series within 12 m (Table 2). Among those with 2 y of continuous medical and pharmacy enrollment, 7,763/9,264 (83.8%) completed the series within 2 y (Table 2). Table 2.Shingrix series completion by year of eligibility, 2018–2024.Dose CompletionOverall(N, %)2018(N, %)2019(N, %)2020(N, %)2021(N, %)2022(N, %)2023(N, %)2024(N, %)N = 15,223N = 503N = 858N = 2,096N = 3,116N = 2,935N = 2,936N = 2,779Second Dose Completed by 6 M9,531 (62.6%)321 (63.8%)551 (64.2%)1,335 (63.7%)1,934 (62.1%)1,814 (61.8%)1,878 (64.0%)1,698 (61.1%)Second Dose Completed by 1 Y11,340 (74.5%)373 (74.2%)645 (75.2%)1,571 (75.0%)2,304 (73.9%)2,191 (74.7%)2,236 (76.2%)2,020 (72.7%)Among Those with 2 Y of Continuous Enrollment**N = 9,264N = 306N = 736N = 1,762N = 2,453N = 2,202N = 1,805–Second Dose Completed by 2 Y7,763 (83.8%)240 (78.4%)607 (82.5%)1,459 (82.8%)2,050 (83.6%)1,856 (84.3%)1,551 (85.9%)–*Counts reflect those who received first dose of Shingrix within 1 y of turning 50.**Counts reflect those who received first dose within 1 y of turning 50 and who had 2 y of continuous enrollment after their 50th birthday. Because continuous enrollment periods were defined based on an individuals’ 50th birthday, not the date of their first Shingrix vaccination, these rates will systematically underestimate completion among those who are late initiators, i.e. receive the vaccine close to their 51st birthday. Shingrix series completion by year of eligibility, 2018–2024. *Counts reflect those who received first dose of Shingrix within 1 y of turning 50. **Counts reflect those who received first dose within 1 y of turning 50 and who had 2 y of continuous enrollment after their 50th birthday. Because continuous enrollment periods were defined based on an individuals’ 50th birthday, not the date of their first Shingrix vaccination, these rates will systematically underestimate completion among those who are late initiators, i.e. receive the vaccine close to their 51st birthday. Cumulative incidence of Shingrix vaccination in the first 3 y of eligibility We observed an increase in the proportion of patients receiving their first Shingrix vaccine within their first year of eligibility (i.e. while they were 50 y of age), rising from 2.6% in 2018 to 14.0% in 2024 (Figure 1). Among individuals with 2 y of continuous medical and pharmacy claims coverage after turning 50, rates increased from 7.3% receiving the vaccine within 2 y of turning 50 in 2018 to 22.1% in 2023. For those with 3 y of continuous medical and pharmacy enrollment, rates increased from 14.3% of adults receiving the vaccine within 3 y of their 50th birthday if they turned 50 in 2018 to 27.5% of those turning 50 in 2022. Survival plots of vaccination within 24 m of eligibility demonstrate that uptake within the first 6 months of eligibility has rapidly increased over calendar time (Figure S1). Shingles vaccine uptake in the first 3 y after eligibility for patients turning 50 in 2018–2024. Predictors of receipt of first dose of Shingrix within 1 y of eligibility We observed several sociodemographic and clinical factors associated with vaccination (Figure 2, Supplementary Table S2). Women had higher odds of vaccination than men (adjusted odds ratio [OR] = 1.19, 95% CI 1.15–1.24). Compared with White adults, Asian adults had higher odds of vaccination (OR = 1.43, 95% CI 1.34–1.53), whereas Black or African American (referred to as Black) adults (OR = 0.75, 95% CI 0.71–0.79) had lower odds of vaccination. Adults with cardiovascular disease (OR = 0.93, 95% CI 0.90–0.97) had lower odds of receiving Shingrix. Rural residence was associated with lower odds of vaccination compared with urban residence (OR = 0.78, 95% CI 0.73–0.84). Adjusted odds ratios for model of any dose of Shingrix within 1 y vs. no dose. Receipt of an influenza vaccine during the first year of eligibility was the strongest non-time-based predictor of shingles vaccination (OR = 1.96, 95% CI 1.88–2.03). Higher healthcare utilization in the year prior to eligibility was also associated with increased odds of vaccination (OR = 1.17, 95% CI 1.12–1.23). Those with a history of shingles disease had increased odds of vaccination (OR = 1.44, 95% CI: 1.31–1.57), and those with Medicaid/CHIP had lower odds of vaccination than those with commercial insurance (OR = 0.59, 95% CI: 0.57–0.62). Marked temporal increases in shingles vaccine uptake were observed over the study period: compared with individuals who became eligible in 2018, odds of vaccination increased progressively among later cohorts, from 2019 (OR = 1.79, 95% CI 1.60–2.00) through 2024 (OR = 6.31, 95% CI 5.72–6.96). Results were robust and consistent in time-to-event sensitivity analyses (Table S3). Predictors of completion of the Shingrix series Among individuals who initiated the Shingrix vaccine series, several sociodemographic, clinical, utilization, geographic, and temporal factors were associated with series completion (Figure 3, Supplementary Table S4). Compared with White adults, Black adults had substantially lower odds of completion at 6 m and 1 y (OR = 0.61, 95% CI: 0.55–0.69; OR = 0.64, 95% CI: 0.57–0.72). Women were more likely to complete the vaccine series within 6 m and 1 y (OR = 1.19, 95% CI 1.12–1.28; OR = 1.19, 95% CI: 1.11–1.29, respectively). Higher healthcare utilization in the year prior to eligibility was also predictive of increased completion at 6 m after the first dose (OR 1.14, 95% CI: 1.05–1.24) and 1 y (OR = 1.17, 95% CI: 1.06–1.28). Those with Medicaid/CHIP insurance had lower odds of series completion at both time points (OR = 0.64, 95% CI: 0.59–0.70 at 6 m and OR = 0.59, 95% CI: 0.53–0.64 at 1 y). There were no significant associations observed for eligibility year, history of shingles disease, or comorbid CVD, T2D, or obesity. Adjusted odds ratios of completing the Shingrix series at 6 m and 1 y after initiation of the first dose. Discussion We observed a marked increase in Shingrix vaccine uptake among newly eligible adults over time, increasing from under 3% of newly-50-y-olds in 2018 receiving Shingrix within a year to 14% of newly 50-y-olds in 2024. Vaccination uptake within 2 y reached a high of 22% for those turning 50 in 2023, and over 27% for 3 y uptake among those turning 50 in 2022. These findings highlight that over a quarter of newly eligible 50-y-olds in 2022 received their first Shingrix vaccination within 3 y, a rapid increase in vaccine uptake since the vaccine was approved in 2018. These results support existing research that shows increased uptake of Shingrix since its licensure12,17,18 and extends those findings to continued increases in uptake throughout 2025. These increasing rates of vaccination uptake among the youngest population eligible for the vaccine highlight increased acceptability and interest in HZ vaccines among an age group that has typically shown lower rates of vaccination than adults over 65.3,19 We also found high rates of completion within 6 m (~63%) and 1 y (~75%), which are aligned well with rates described by other studies representing populations aged 50+. Because continuous enrollment periods were defined based on an individual’s 50th birthday, these rates are conservative, potentially underestimating completion among those who are late initiators. This highlights that vaccine ‘early adopters’ who receive Shingrix right at age 50 do not seem to have meaningfully different completion rates as older adults.14,20,21 Our models showed an acceleration of Shingrix uptake within the first year of eligibility in 2023 and 2024, which may reflect a number of factors, including greater acceptability of the vaccine after years on the market, improved provider prescribing of the vaccine, or improved awareness of the vaccine from patients. While we do not have the evidence to evaluate secular trends that may have improved vaccination coverage, it is worth mentioning that in May 2023, a preprint was published showing eligibility of receiving shingles vaccination associated with a significant reduction in incident dementia risk,22 and further research in 202410 and 20258,9 supporting the relationship between HZ vaccination and reduction in dementia risk. We also saw that women were more likely to receive a first dose of Shingrix, in line with prior literature,13,19 and more likely to complete the vaccine series compared to men. Women also have greater primary and preventive healthcare utilization than men,23 which may lead to both better Shingrix series initiation and completion. Interestingly, a study of VAERS reports from shingles vaccinations showed the majority of reporters were women,24 indicating that women may experience greater reactogenicity from the vaccine, however we did not see any evidence that women have reduced series completion. We noted sociodemographic predictors of Shingrix uptake within 1 y consistent with previous literature, including that Black adults had substantially lower odds of Shingrix vaccination and series completion than White adults.20,25 These findings aligned with a prior study using BRFSS data which found Black respondents had 50% lower odds of receiving the shingles vaccine in 2017 and 45% lower odds in 2020 than White counterparts.13 There are likely a myriad of contributing factors to these disparities in Shingrix vaccination and series completion among Black adults, including historical and persistent mistrust of healthcare institutions and structural racism.13,26 The magnitude of sociodemographic predictors on Shingrix vaccination within 1 y was similar to those in reported literature for all adults over 50, indicating that we did not see a drastically different sociodemographic profile for patients receiving Shingrix in their first year of eligibility. Individuals who had documented history of shingles infection had increased odds of first vaccination within 1 y, perhaps indicating that individuals who have experienced shingles disease understand its severity and are more inclined to receive the vaccine when first eligible to prevent recurrences. Residents of rural areas were significantly less likely to receive a dose of Shingrix in the first year of eligibility, matching observed trends reported for influenza vaccinations.27 Influenza vaccination during a patient’s 50th year was a strong predictor of Shingrix uptake within 1 y, supporting existing evidence that those who engage with preventive care and receive seasonal vaccinations are much more likely to receive other vaccinations.19,28,29 Importantly, Shingrix can be co-administered safely with influenza vaccines, and thus providers may want to encourage patients to receive both vaccines on the same day to improve vaccination rates further.30 We also saw odds of first vaccination and completion of the series vary by insurance type, specifically with those individuals with Medicaid/CHIP having reduced odds of both first dose and completion compared to those with commercial insurance. Strengths and limitations This study has several strengths. First, the analysis leveraged a cohort of adults turning 50 in Truveta’s EHR data with linked medical and pharmacy claims. This allowed for a more complete longitudinal health picture for these patients and enabled the use of comorbidity data from EHR and complete vaccine capture from pharmacy and medical claims, in addition to EHR records of vaccine administration. Additionally, these data are extremely recent, including vaccines administered and captured in EHR and claims through the end of September 2025. Our study also faces some limitations. The population was restricted to individuals with 1-, 2-, and 3-y of continuous pharmacy and medical enrollment for the different follow up cohorts, and these individuals may represent a slightly different population with both a medical home and continuous insurance coverage, limiting generalizability to non-insured populations. Due to not requiring full patient histories, capture of comorbidities and prior shingles disease may be under-reported. We were unable to distinguish between patient- and provider-level factors and also were unable to assess reasons for non-vaccination or series completion. Additionally, because we assessed incident vaccinations in those newly eligible, we did not explore complete prevalence of Shingrix uptake among all adults 50 and older. Conclusions Shingrix vaccine uptake has increased rapidly since its approval, with an estimated 27% of immunocompetent individuals who became eligible for the vaccine in 2022 receiving a first dose within 3 y. As evidence continues to build supporting a relationship between herpes zoster vaccination and dementia prevention, it is important to understand the characteristics of the persons receiving Shingrix immediately upon entering eligibility. Clinicians can seek to further improve Shingrix uptake through offering coadministration with influenza vaccination and improve disparities through targeted outreach to Black adults and residents of rural areas. Supplementary Material Supplementary Appendix.docx Acknowledgments The authors thank Paul Carroll, Truveta Inc, for providing support and implementation for linked closed claims. Biography Nina B. Masters is a Principal Applied Research Scientist at Truveta, with a PhD and MPH in epidemiology. She focuses on research pertaining to infectious diseases, vaccination uptake, policy, and disparities, and disease dynamics. Funding Statement Truveta provided funding for this study. Disclosure statement All authors are employees of Truveta, Inc. and hold equity in the company. Supplementary material Supplemental data for this article can be accessed online at https://doi.org/10.1080/21645515.2026.2687231 References Associated Data Supplementary Materials Supplementary Appendix.docx